Enalare Therapeutics Inc. is a privately owned clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients suffering from acute respiratory conditions.
Corporate Profile
Events
August 26-29th, 2024
Enalare Therapeutic Presents at the Military Health System Research Symposium 2024
April 10-14th, 2024
Enalare Therapeutic Presents at the American College of Medical Toxicology
June 18th, 2023
Poster M31 -Novel ‘Agnostic’ Pharmacologic Approach to Polysubstance Overdose
Poster S119 – Safety and Tolerability of Ascending Doses of ENA-001: A Novel Respiratory Stimulant, for the Intended Management of Pharmacologically-Induced Respiratory Depression
December 6th, 2022
Featured speakers and KOLs include: Scott Tarriff, Herm Cukier, Dr. Richard Dutton, Dr. Prem Fort, Dr. TJ Gan, Dr. Andre Kalil, Dr. Joseph Pergolizzi and Dr. Eugene Vortsman — — Topics include the clinical and scientific rationale for the Company’s hospital-based products and pipeline
May 2nd, 2022
Herm Cukier, President and Chief Executive Officer, will be presenting at the BioNJ’s Twelfth Annual BioPartnering Conference and Chief Operating Officer, Daniel Motto, will be taking questions after the presentation and meeting with potential investors and strategic partners.
December 28th, 2021
Herm Cukier, President and CEO of Enalare Therapeutics, will provide an update on the Company’s ongoing clinical development program as well as progress on other scientific endeavors. The presentations will be available for viewing on-demand beginning on Jan. 10, 2022 via the H.C. Wainright Bioconnect Conference and the Biotech Showcase 2022 Conference platforms.
May 24th, 2021
Herm Cukier, President and Chief Executive Officer, presents at the BioNJ’s Eleventh Annual BioPartnering Conference.
February 3rd, 2021
Herm Cukier, President and Chief Executive Officer, and Daniel Motto, Chief Operating Officer, will be presenting at the BIO-Europe Spring Conference scheduled for March 22-25, 2021.
Resources
- Are opioid receptor antagonists adequate for “Opioid” overdose in a changing reality?
- History of Respiratory Stimulants
- Commentary: New Complications Make Treatment of “Opioid” Overdose Challenging
- Commentary: “Ockham’s Razor” Doesn’t Apply to “Opioid” Overdose Death
- Prediction of Opioid-Induced Respiratory Depression on Inpatient Wards Using Continuous Capnography and Oximetry: An International Prospective, Observational Trial
- The Polysubstance Overdose-Death Crisis
- Increase in Fatal Drug Overdoses Across the United States Driven by Synthetic Opioids Before and During the COVID-19 Pandemic
- The problem of postoperative respiratory depression